THE EFFICACY AND SAFETY OF LURASIDONE IN ADOLESCENT PATIENTS WITH SCHIZOPHRENIA: A 6-WEEK, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY

被引:0
|
作者
Goldman, Robert S. [1 ]
Findling, Robert L. [1 ]
Silva, Robert M. [1 ]
Cucchiaro, Josephine B. [1 ]
Deng, Ling [1 ]
Loebel, Antony [1 ]
机构
[1] Sunovion Pharmaceut Inc, 84 Waterford Dr, Marlborough, MA 01752 USA
关键词
D O I
10.1016/j.jaac.2016.09.199
中图分类号
B844 [发展心理学(人类心理学)];
学科分类号
040202 ;
摘要
4.4
引用
收藏
页码:S163 / S164
页数:2
相关论文
共 50 条
  • [1] The Efficacy and Safety of Lurasidone in Adolescent Patients With Schizophrenia: A 6-Week, Double-Blind, Placebo-Controlled, Multicenter Study
    Correll, Christoph U.
    Goldman, Robert
    Silva, Robert
    Cucchiaro, Josephine
    Deng, Ling
    Loebel, Antony
    [J]. NEUROPSYCHOPHARMACOLOGY, 2016, 41 : S597 - S598
  • [2] The efficacy of lurasidone on PANSS subscales in adolescent patients with schizophrenia: Results from a 6-week, double-blind, placebo-controlled, multicenter study
    Correll, C.
    Goldman, R.
    Cucchiaro, J.
    Deng, L.
    Loebel, A.
    [J]. EUROPEAN PSYCHIATRY, 2017, 41 : S90 - S91
  • [3] Efficacy and safety of lurasidone in acutely psychotic patients with schizophrenia: A 6-week, randomized, double-blind, placebo-controlled study
    Iyo, Masaomi
    Ishigooka, Jun
    Nakamura, Masatoshi
    Sakaguchi, Reiko
    Okamoto, Keisuke
    Mao, Yongcai
    Tsai, Joyce
    Fitzgerald, Alison
    Nosaka, Tadashi
    Higuchi, Teruhiko
    [J]. PSYCHIATRY AND CLINICAL NEUROSCIENCES, 2021, 75 (07) : 227 - 235
  • [4] Efficacy and safety of lurasidone in acutely psychotic patients with schizophrenia: A 6-week, randomized, double-blind, placebo-controlled study
    Iyo, Masaomi
    Ishigooka, Jun
    Nakamura, Masatoshi
    Sakaguchi, Reiko
    Okamoto, Keisuke
    Mao, Yongcai
    Tsai, Joyce
    Fitzgerald, Alison
    Nosaka, Tadashi
    Higuchi, Teruhiko
    [J]. PSYCHIATRY AND CLINICAL NEUROSCIENCES, 2021, : 227 - 235
  • [5] The efficacy and safety of lurasidone in adolescent patients with schizophrenia: Results of functional and quality of life measures from a 6-week, double-blind, placebo-controlled study
    Findling, R.
    Goldman, R.
    Cucchiaro, J.
    Deng, L.
    Loebel, A.
    [J]. EUROPEAN PSYCHIATRY, 2017, 41 : S94 - S94
  • [6] Efficacy and safety of blonanserin transdermal patch in patients with schizophrenia: A 6-week randomized, double-blind, placebo-controlled, multicenter study
    Iwata, Nakao
    Ishigooka, Jun
    Kim, Won-Hyoung
    Yoon, Bo-Hyun
    Lin, Shih-Ku
    Sulaiman, Ahmad Hatim
    Cosca, Rowena
    Wang, Lina
    Suchkov, Yury
    Agarkov, Alexey
    Watabe, Kei
    Matsui, Tomohito
    Sato, Takayuki
    Inoue, Yoshifumi
    Higuchi, Teruhiko
    Correll, Christoph U.
    Kane, John M.
    [J]. SCHIZOPHRENIA RESEARCH, 2020, 215 : 408 - 415
  • [7] Efficacy and safety of lurasidone in adolescents and young adults with schizophrenia: Pooled analysis of double-blind, placebo-controlled 6-week studies
    Calisti, F.
    Costamagna, I.
    Hsu, J.
    Tocco, M.
    Pikalov, A.
    Goldman, R.
    [J]. EUROPEAN PSYCHIATRY, 2021, 64 : S166 - S166
  • [8] A 6-Week, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Risperidone in Adolescents with Schizophrenia
    Haas, Magali
    Unis, Alan S.
    Armenteros, Jorge
    Copenhaver, Margaret D.
    Quiroz, Jorge A.
    Kushner, Stuart F.
    [J]. JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY, 2009, 19 (06) : 611 - 621
  • [9] Efficacy and Safety of Lurasidone in Adolescents with Schizophrenia: A 6-Week, Randomized Placebo-Controlled Study
    Goldman, Robert
    Loebel, Antony
    Cucchiaro, Josephine
    Deng, Ling
    Findling, Robert L.
    [J]. JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY, 2017, 27 (06) : 516 - 525
  • [10] Efficacy and safety of lurasidone in adolescents and young adults with schizophrenia: pooled analysis of double-blind, placebo-controlled 6-week studies
    Costamagna, I.
    Calisti, F.
    Hsu, J.
    Tocco, M.
    Pikalov, A.
    Goldman, R.
    [J]. EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2020, 40 : S473 - S474